Associations of non‐alcoholic fatty liver disease and cirrhosis with liver cancer in European and East Asian populations: A Mendelian randomization study

Abstract

Abstract Background The positive relationships of non‐alcoholic fatty liver disease (NAFLD) and cirrhosis with liver cancer were shown in previous observational studies, while further Mendelian randomization (MR) investigations are needed to confirm the possible causal associations. Aims This study aimed to explore whether NAFLD and cirrhosis were causally related to liver cancer using MR in European and East Asian populations. Methods and Results For European populations, NAFLD data were obtained from a genome‐wide meta‐analysis (8434 patients and 770 180 controls). The data on chronic elevation of alanine aminotransferase (cALT), a proxy of NAFLD, were derived from Million Veteran Program (68 725 patients and 95 472 controls). Cirrhosis data were collected from two sources: a genome‐wide association study of five cohorts (4829 patients and 72 705 controls) and FinnGen (1931 patients and 216 861 controls). Liver cancer data were collected from FinnGen (304 patients and 174 006 controls). For East Asian populations, the data on cirrhosis (2184 patients and 210 269 controls) and hepatocellular carcinoma (1866 patients and 195 745 controls) were obtained from Biobank Japan. Three, 41, seven, six, and three single‐nucleotide polymorphisms were used for NAFLD (European), cALT (European), cirrhosis (European‐five cohorts), cirrhosis (European‐FinnGen), and cirrhosis (East Asian), respectively. We used inverse‐variance weighted as the primary method to calculate the odds ratio (OR) and 95% confidence interval (CI). Among European populations, genetically‐predicted NAFLD, cALT, cirrhosis (five cohorts), and cirrhosis (FinnGen) were positively associated with liver cancer, with ORs (95% CIs) of 6.62 (3.81–11.50) (p < .001), 2.59 (1.70–3.94) (p < .001), 3.38 (2.41–4.75) (p < .001), and 2.62 (1.20–5.72) (p = .015). Among East Asian populations, there was also a positive association between genetically‐predicted cirrhosis and hepatocellular carcinoma (OR = 2.12; 95% CI = 1.78–2.52; p < .001). Conclusion This study utilized MR to complementarily confirm the positive connections of NAFLD and cirrhosis with liver cancer, as identified in earlier observational research. Subsequent MR investigations involving more liver cancer cases are needed.

Keywords

• cirrhosis
• hepatocellular carcinoma
• liver cancer
• Mendelian randomization
• non‐alcoholic fatty liver disease